Survival Advantage of Coagulation Factor XI–Deficient Mice during Peritoneal Sepsis
Authors:
Open Access
- 15 July 2008
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 198 (2) , 271-274
Abstract
Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of theKeywords
This publication has 15 references indexed in Scilit:
- Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasisJournal of Experimental Medicine, 2006
- A Protein C Deficiency Exacerbates Inflammatory and Hypotensive Responses in Mice During Polymicrobial Sepsis in a Cecal Ligation and Puncture ModelThe American Journal of Pathology, 2004
- Factor XI–dependence of surface- and tissue factor–initiated thrombus propagation in primatesBlood, 2003
- High Levels of Coagulation Factor XI as a Risk Factor for Venous ThrombosisNew England Journal of Medicine, 2000
- Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseasesNature Medicine, 1998
- Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.Journal of Clinical Investigation, 1998
- A murine model of factor XI deficiencyBlood Coagulation & Fibrinolysis, 1997
- The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.Journal of Clinical Investigation, 1993
- Factor XI Deficiency in Ashkenazi Jews in IsraelNew England Journal of Medicine, 1991
- Activation and Inhibition of Hageman Factor-Dependent Pathways and the Complement System in Uncomplicated Bacteremia or Bacterial ShockThe Journal of Infectious Diseases, 1985